Do analysts prefer DTSQ or ATNM?

Actinium Pharmaceuticals has a consensus price target of $5.00, suggesting a potential upside of 525.00%. Given Actinium Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Actinium Pharmaceuticals is more favorable than DT Cloud Star Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score DT Cloud Star Acquisition 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Actinium Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Which has stronger earnings and valuation, DTSQ or ATNM?

DT Cloud Star Acquisition has higher earnings, but lower revenue than Actinium Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DT Cloud Star Acquisition N/A N/A N/A N/A N/A Actinium Pharmaceuticals $90K 278.89 -$48.82M $0.36 2.22

Is DTSQ or ATNM more profitable?

DT Cloud Star Acquisition's return on equity of 0.00% beat Actinium Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets DT Cloud Star Acquisition N/A N/A N/A Actinium Pharmaceuticals N/A -100.85% -47.89%

Is BDTX or ATNM more profitable?

Black Diamond Therapeutics' return on equity of -32.10% beat Actinium Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Black Diamond Therapeutics N/A -32.10% -25.21% Actinium Pharmaceuticals N/A -100.85% -47.89%

Is RANI or ATNM more profitable?

Actinium Pharmaceuticals' return on equity of -100.85% beat Rani Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Rani Therapeutics N/A -206.46% -83.95% Actinium Pharmaceuticals N/A -100.85% -47.89%

Is ATNM or PCSC more profitable?

Perceptive Capital Solutions' return on equity of -2.70% beat Actinium Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Actinium Pharmaceuticals N/A -100.85% -47.89% Perceptive Capital Solutions N/A -2.70% -0.84%

Actinium Pharmaceuticals (ATNM) Competitors

$0.80 +0.00 (+0.33%)

As of 10:04 AM Eastern

Compare

ATNM vs. DTSQ, BDTX, RANI, AADI, and PCSC

Should you buy Actinium Pharmaceuticals stock or one of its competitors? MarketBeat compares Actinium Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Actinium Pharmaceuticals include DT Cloud Star Acquisition (DTSQ), Black Diamond Therapeutics (BDTX), Rani Therapeutics (RANI), Aadi Bioscience (AADI), and Perceptive Capital Solutions (PCSC). These companies are all part of the "biotechnology" industry.

How does Actinium Pharmaceuticals compare to DT Cloud Star Acquisition?

DT Cloud Star Acquisition (NASDAQ:DTSQ) and Actinium Pharmaceuticals (NYSE:ATNM) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, analyst recommendations, risk, media sentiment, earnings and dividends.

In the previous week, DT Cloud Star Acquisition had 2 more articles in the media than Actinium Pharmaceuticals. MarketBeat recorded 2 mentions for DT Cloud Star Acquisition and 0 mentions for Actinium Pharmaceuticals. DT Cloud Star Acquisition's average media sentiment score of 0.69 beat Actinium Pharmaceuticals' score of 0.00 indicating that DT Cloud Star Acquisition is being referred to more favorably in the media.

Company	Overall Sentiment
DT Cloud Star Acquisition	Positive
Actinium Pharmaceuticals	Neutral

DT Cloud Star Acquisition's return on equity of 0.00% beat Actinium Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DT Cloud Star Acquisition	N/A	N/A	N/A
Actinium Pharmaceuticals	N/A	-100.85%	-47.89%

27.5% of Actinium Pharmaceuticals shares are held by institutional investors. 52.9% of DT Cloud Star Acquisition shares are held by company insiders. Comparatively, 0.6% of Actinium Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

DT Cloud Star Acquisition has higher earnings, but lower revenue than Actinium Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DT Cloud Star Acquisition	N/A	N/A	N/A	N/A	N/A
Actinium Pharmaceuticals	$90K	278.89	-$48.82M	$0.36	2.22

DT Cloud Star Acquisition has a beta of -0.01, suggesting that its stock price is 101% less volatile than the broader market. Comparatively, Actinium Pharmaceuticals has a beta of 0.01, suggesting that its stock price is 99% less volatile than the broader market.

Actinium Pharmaceuticals has a consensus price target of $5.00, suggesting a potential upside of 525.00%. Given Actinium Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Actinium Pharmaceuticals is more favorable than DT Cloud Star Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DT Cloud Star Acquisition	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Actinium Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Actinium Pharmaceuticals beats DT Cloud Star Acquisition on 6 of the 11 factors compared between the two stocks.

How does Actinium Pharmaceuticals compare to Black Diamond Therapeutics?

Black Diamond Therapeutics (NASDAQ:BDTX) and Actinium Pharmaceuticals (NYSE:ATNM) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.

Black Diamond Therapeutics presently has a consensus target price of $9.83, suggesting a potential upside of 405.57%. Actinium Pharmaceuticals has a consensus target price of $5.00, suggesting a potential upside of 525.00%. Given Actinium Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Actinium Pharmaceuticals is more favorable than Black Diamond Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Black Diamond Therapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Actinium Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Black Diamond Therapeutics' return on equity of -32.10% beat Actinium Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Black Diamond Therapeutics	N/A	-32.10%	-25.21%
Actinium Pharmaceuticals	N/A	-100.85%	-47.89%

Black Diamond Therapeutics has higher revenue and earnings than Actinium Pharmaceuticals. Black Diamond Therapeutics is trading at a lower price-to-earnings ratio than Actinium Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Black Diamond Therapeutics	$70M	1.60	$22.37M	-$0.75	N/A
Actinium Pharmaceuticals	$90K	278.89	-$48.82M	$0.36	2.22

95.5% of Black Diamond Therapeutics shares are owned by institutional investors. Comparatively, 27.5% of Actinium Pharmaceuticals shares are owned by institutional investors. 9.3% of Black Diamond Therapeutics shares are owned by insiders. Comparatively, 0.6% of Actinium Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Black Diamond Therapeutics has a beta of 3.28, meaning that its stock price is 228% more volatile than the broader market. Comparatively, Actinium Pharmaceuticals has a beta of 0.01, meaning that its stock price is 99% less volatile than the broader market.

In the previous week, Black Diamond Therapeutics had 12 more articles in the media than Actinium Pharmaceuticals. MarketBeat recorded 12 mentions for Black Diamond Therapeutics and 0 mentions for Actinium Pharmaceuticals. Black Diamond Therapeutics' average media sentiment score of 1.47 beat Actinium Pharmaceuticals' score of 0.00 indicating that Black Diamond Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Black Diamond Therapeutics	Positive
Actinium Pharmaceuticals	Neutral

Summary

Black Diamond Therapeutics beats Actinium Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does Actinium Pharmaceuticals compare to Rani Therapeutics?

Rani Therapeutics (NASDAQ:RANI) and Actinium Pharmaceuticals (NYSE:ATNM) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, risk, dividends, institutional ownership, media sentiment and profitability.

Actinium Pharmaceuticals' return on equity of -100.85% beat Rani Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rani Therapeutics	N/A	-206.46%	-83.95%
Actinium Pharmaceuticals	N/A	-100.85%	-47.89%

Rani Therapeutics has a beta of 0.78, indicating that its stock price is 22% less volatile than the broader market. Comparatively, Actinium Pharmaceuticals has a beta of 0.01, indicating that its stock price is 99% less volatile than the broader market.

30.2% of Rani Therapeutics shares are held by institutional investors. Comparatively, 27.5% of Actinium Pharmaceuticals shares are held by institutional investors. 26.7% of Rani Therapeutics shares are held by insiders. Comparatively, 0.6% of Actinium Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Rani Therapeutics had 3 more articles in the media than Actinium Pharmaceuticals. MarketBeat recorded 3 mentions for Rani Therapeutics and 0 mentions for Actinium Pharmaceuticals. Rani Therapeutics' average media sentiment score of 1.51 beat Actinium Pharmaceuticals' score of 0.00 indicating that Rani Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Rani Therapeutics	Very Positive
Actinium Pharmaceuticals	Neutral

Rani Therapeutics currently has a consensus target price of $8.75, suggesting a potential upside of 1,007.59%. Actinium Pharmaceuticals has a consensus target price of $5.00, suggesting a potential upside of 525.00%. Given Rani Therapeutics' higher possible upside, equities research analysts plainly believe Rani Therapeutics is more favorable than Actinium Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rani Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Actinium Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Rani Therapeutics has higher revenue and earnings than Actinium Pharmaceuticals. Rani Therapeutics is trading at a lower price-to-earnings ratio than Actinium Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rani Therapeutics	$1.63M	60.04	-$29.67M	-$0.41	N/A
Actinium Pharmaceuticals	$90K	278.89	-$48.82M	$0.36	2.22

Summary

Rani Therapeutics beats Actinium Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Actinium Pharmaceuticals compare to Aadi Bioscience?

Actinium Pharmaceuticals (NYSE:ATNM) and Aadi Bioscience (NASDAQ:AADI) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, earnings, profitability, media sentiment, analyst recommendations, risk and institutional ownership.

Actinium Pharmaceuticals currently has a consensus price target of $5.00, indicating a potential upside of 525.00%. Given Actinium Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe Actinium Pharmaceuticals is more favorable than Aadi Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Actinium Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Aadi Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Actinium Pharmaceuticals has higher earnings, but lower revenue than Aadi Bioscience. Aadi Bioscience is trading at a lower price-to-earnings ratio than Actinium Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Actinium Pharmaceuticals	$90K	278.89	-$48.82M	$0.36	2.22
Aadi Bioscience	$25.07M	4.69	-$65.76M	-$2.35	N/A

In the previous week, Actinium Pharmaceuticals' average media sentiment score of 0.00 equaled Aadi Bioscience'saverage media sentiment score.

Company	Overall Sentiment
Actinium Pharmaceuticals	Neutral
Aadi Bioscience	Neutral

Actinium Pharmaceuticals has a beta of 0.01, meaning that its stock price is 99% less volatile than the broader market. Comparatively, Aadi Bioscience has a beta of 0.68, meaning that its stock price is 32% less volatile than the broader market.

27.5% of Actinium Pharmaceuticals shares are held by institutional investors. Comparatively, 52.1% of Aadi Bioscience shares are held by institutional investors. 0.6% of Actinium Pharmaceuticals shares are held by company insiders. Comparatively, 37.3% of Aadi Bioscience shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Actinium Pharmaceuticals has a net margin of 0.00% compared to Aadi Bioscience's net margin of -246.06%. Aadi Bioscience's return on equity of -71.87% beat Actinium Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Actinium Pharmaceuticals	N/A	-100.85%	-47.89%
Aadi Bioscience	-246.06%	-71.87%	-57.28%

Summary

Actinium Pharmaceuticals beats Aadi Bioscience on 9 of the 14 factors compared between the two stocks.

How does Actinium Pharmaceuticals compare to Perceptive Capital Solutions?

Actinium Pharmaceuticals (NYSE:ATNM) and Perceptive Capital Solutions (NASDAQ:PCSC) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation, risk and media sentiment.

Perceptive Capital Solutions' return on equity of -2.70% beat Actinium Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Actinium Pharmaceuticals	N/A	-100.85%	-47.89%
Perceptive Capital Solutions	N/A	-2.70%	-0.84%

Actinium Pharmaceuticals presently has a consensus target price of $5.00, suggesting a potential upside of 525.00%. Given Actinium Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Actinium Pharmaceuticals is more favorable than Perceptive Capital Solutions.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Actinium Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Perceptive Capital Solutions	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

27.5% of Actinium Pharmaceuticals shares are held by institutional investors. 0.6% of Actinium Pharmaceuticals shares are held by company insiders. Comparatively, 22.1% of Perceptive Capital Solutions shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Perceptive Capital Solutions has lower revenue, but higher earnings than Actinium Pharmaceuticals. Perceptive Capital Solutions is trading at a lower price-to-earnings ratio than Actinium Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Actinium Pharmaceuticals	$90K	278.89	-$48.82M	$0.36	2.22
Perceptive Capital Solutions	N/A	N/A	$840K	-$0.06	N/A

In the previous week, Actinium Pharmaceuticals' average media sentiment score of 0.00 equaled Perceptive Capital Solutions'average media sentiment score.

Company	Overall Sentiment
Actinium Pharmaceuticals	Neutral
Perceptive Capital Solutions	Neutral

Actinium Pharmaceuticals has a beta of 0.01, meaning that its stock price is 99% less volatile than the broader market. Comparatively, Perceptive Capital Solutions has a beta of 0.36, meaning that its stock price is 64% less volatile than the broader market.

Summary

Actinium Pharmaceuticals beats Perceptive Capital Solutions on 7 of the 12 factors compared between the two stocks.

Get Actinium Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ATNM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ATNM vs. The Competition

Export

Metric	Actinium Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NYSE Exchange
Market Cap	$25.10M	$3.71B	$7.02B	$24.16B
Dividend Yield	N/A	3.76%	2.58%	3.69%
P/E Ratio	-0.58	9.07	269.90	29.13
Price / Sales	278.89	1,294.66	659.13	14.39
Price / Cash	N/A	44.95	28.89	19.37
Price / Book	0.61	17.71	11.29	4.91
Net Income	-$48.82M	-$13.25M	$3.45B	$1.06B
7 Day Performance	-1.42%	5.42%	3.56%	1.35%
1 Month Performance	-13.98%	-1.71%	-0.57%	2.32%
1 Year Performance	-48.05%	61.70%	77.67%	20.14%

Actinium Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ATNM Actinium Pharmaceuticals	1.725 of 5 stars	$0.80 +0.3%	$5.00 +525.0%	-48.2%	$25.10M	$90K	N/A	30
DTSQ DT Cloud Star Acquisition	1.3126 of 5 stars	$11.33 +0.1%	N/A	+6.8%	$100.76M	N/A	N/A	N/A	Earnings Report
BDTX Black Diamond Therapeutics	3.4224 of 5 stars	$1.78 +2.6%	$9.83 +452.4%	-18.8%	$99.42M	$70M	N/A	90	Positive News Earnings Report Analyst Revision
RANI Rani Therapeutics	3.2747 of 5 stars	$0.82 +2.3%	$8.75 +967.1%	+50.0%	$99.27M	$1.63M	N/A	110	Positive News
AADI Aadi Bioscience	N/A	$3.96 +2.9%	N/A	+172.0%	$97.80M	$25.07M	N/A	40

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:ATNM) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Actinium Pharmaceuticals (ATNM) Competitors

ATNM vs. DTSQ, BDTX, RANI, AADI, and PCSC

How does Actinium Pharmaceuticals compare to DT Cloud Star Acquisition?

Summary

How does Actinium Pharmaceuticals compare to Black Diamond Therapeutics?

Summary

How does Actinium Pharmaceuticals compare to Rani Therapeutics?

Summary

How does Actinium Pharmaceuticals compare to Aadi Bioscience?

Summary

How does Actinium Pharmaceuticals compare to Perceptive Capital Solutions?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATNM vs. The Competition

Actinium Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Actinium Pharmaceuticals (ATNM) Competitors

ATNM vs. DTSQ, BDTX, RANI, AADI, and PCSC

How does Actinium Pharmaceuticals compare to DT Cloud Star Acquisition?

Does the media favor DTSQ or ATNM?

Is DTSQ or ATNM more profitable?

Do insiders & institutionals hold more shares of DTSQ or ATNM?

Which has stronger earnings and valuation, DTSQ or ATNM?

Which has more volatility & risk, DTSQ or ATNM?

Do analysts prefer DTSQ or ATNM?

Summary

How does Actinium Pharmaceuticals compare to Black Diamond Therapeutics?

Do analysts recommend BDTX or ATNM?

Is BDTX or ATNM more profitable?

Which has higher valuation and earnings, BDTX or ATNM?

Do institutionals and insiders hold more shares of BDTX or ATNM?

Which has more risk & volatility, BDTX or ATNM?

Does the media favor BDTX or ATNM?

Summary

How does Actinium Pharmaceuticals compare to Rani Therapeutics?

Is RANI or ATNM more profitable?

Which has more volatility & risk, RANI or ATNM?

Do institutionals & insiders have more ownership in RANI or ATNM?

Does the media prefer RANI or ATNM?

Do analysts recommend RANI or ATNM?

Which has higher valuation and earnings, RANI or ATNM?

Summary

How does Actinium Pharmaceuticals compare to Aadi Bioscience?

Do analysts recommend ATNM or AADI?

Which has better earnings & valuation, ATNM or AADI?

Does the media refer more to ATNM or AADI?

Which has more volatility and risk, ATNM or AADI?

Do institutionals and insiders have more ownership in ATNM or AADI?

Is ATNM or AADI more profitable?

Summary

How does Actinium Pharmaceuticals compare to Perceptive Capital Solutions?

Is ATNM or PCSC more profitable?

Do analysts recommend ATNM or PCSC?

Do institutionals & insiders hold more shares of ATNM or PCSC?

Which has preferable earnings & valuation, ATNM or PCSC?

Does the media refer more to ATNM or PCSC?

Which has more volatility & risk, ATNM or PCSC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATNM vs. The Competition

Actinium Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools